99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer

Anticancer Research

Volumn 18, Issue 6 B, 1998, Pages 4601-4605

  Fujii, Hirofumi ^a   Nakamura, Kayoko ^a   Kubo, Atsushi ^a   Enomoto, Kohji ^a   Ikeda, Tadashi ^a   Kubota, Tetsuro ^a   Matsuzaki, Shinjiro Wilson ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

99mTc MIBI; Anthracycline; Breast cancer; Chemosensitivity

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MITOMYCIN; MONOCLONAL ANTIBODY; PIRARUBICIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BREAST CANCER; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMAGING; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SCINTIMAMMOGRAPHY; ADULT; AGED; BREAST TUMOR; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; METABOLISM; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS; SCINTISCANNING;

ADULT; AGED; ANTHRACYCLINES; BREAST NEOPLASMS; CELL SURVIVAL; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; MITOMYCINS; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; TECHNETIUM TC 99M SESTAMIBI; TUMOR CELLS, CULTURED;

EID: 0032217238     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Seeger J and Woodcock TM: Chemotherapy of breast cancer. In: Cancer of the breast (Danegan WL and Sparatt JS, eds). Philadelphia, W. B. Saunders Company, 1995, pp519-528.
2. De-Vincenzo R, Scambia G, Benedetti PP, et al.: Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. Int J Cancer 68: 340-348, 1996.
3. Harstrick A, Vanhoefer U, Schleucher N, et al: Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines. Anticancer Drugs 6: 681-685, 1995.
4. Scambia G, Ranelletti FO, Panici PB, et al: Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target [see comments]. Cancer Chemother Pharmacol 34: 459-464, 1994.
5. Bom H, Kim Y, Song H, et al: Technetium-99m-MIBI uptake in small cell lung cancer. J Nucl Med 39: 91-94, 1998.
6. Sutter CW, Stadalnik RC: Noncardiac uptake of Technetium-99m Sestamibi : An updated Gamut. Seminars in Nucl Med 26: 135-140, 1996.
7. Khalkhali I, Cutrone J, Mena I, et al: Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 36: 1784-1789, 1995.
8. Cordobes MD, Starzec A, Delmon-Moingeon L, et al: Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 37: 286-289, 1996.
9. Derebek E, Kirkali Z, Dogan AS, et al: Tc-99m MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between Tc-99m MIBI uptake and P-glycoprotein expression in tumour tissue. Eur J Nucl Med 23: 976-979, 1996.
10. Piwnica-Worms D, Rao CV, Kronauge JF, Croop JM: Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 34: 12210-12220, 1995.
11. Furukawa T, Kubota T, Watanabe M, et al: Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and the MTT end-point. Anticancer Res 12: 1377-1382, 1992.
12. Furukawa T, Kubota T, Tanino H, et al: Clinical application of histoculture drug response assay (HDRA) -distribution pattern of inhibition index and predictability of clinical chemotherapy effects. J Jpn Soc Cancer Ther 32: 400-409, 1997.
13. Saikawa Y, Kubota T, Furukawa T, et al: Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer. Jpn J Cancer Res 85: 762-765, 1994.
14. Kubota T, Saikawa Y, Furukawa T, Kitajima M: Chemosensitivity test is useful to prolong the survival of the postoperative patients with gastric and colon carcinomas. Jpn J Cancer Digestive Organs 3: 287-293, 1993.
15. Gregorcyk S, Kang Y, Brandt D, et al:P-Glycoprotein expression as a predictor of breast cancer recurrence. Ann Surg Oncol 3: 8-14, 1996.
16. Gibelli N, Zibera C, Sica G, et at: Morphological and biochemical features of a medroxyprogesterone acetate (MPA)-resistant MCF-7 breast cancer cell line. Anticancer Res 14: 37-43, 1994.
17. Pinedo HM: Drug resistance, illustration of the complexity of translational research. Int J Cancer 65: 561-566, 1996.
18. Hegewischbecker S, Staib F, Loning T, et al: No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer. Ann Onco 19: 85-93, 1998.
19. Mechetner E, Kyshtoobayeva A, Zonis S, et al: Levels of multidrug resistance (MDR1)P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389-398, 1998.
20. Ferry D: Testing the role of P-glycoprotein expression in clinical trials - applying pahrmacological principals and best methods for detection together with good clinical trials methodology. Int J Clin Pharmacol Therap 36: 29-40, 1998.